Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 9/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 6/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 6/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31170280 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL17318366 | 0.98 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL342616 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL342614 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL342615 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25021936 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL52844 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4669293 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30306973 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1161371 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | claimed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-10273234-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180111941-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-2879674-B1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9802944-B2 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170008900-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20150203493-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150203493-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2015-07-23 | — | — | US | disclosed |
| WO-2014025708-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008900-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | CHRNB2 2362/4885CHRNA4 2598/4885CHRNB4 2524/4885 |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | CHRNB2 1/4885CHRNA4 3/4885CHRNB4 2/4885 |
| US-20180111941-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | CHRNB2 2362/4885CHRNA4 2598/4885CHRNB4 2524/4885 |
| US-10273234-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | ENPP2, S1PR1, S1PR2 | CHRNB2 150/4885CHRNA4 167/4885CHRNB4 153/4885 |
| US-20150203493-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | CHRNB2 150/4885CHRNA4 167/4885CHRNB4 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.